Grail Stock Soars 35% as FDA Staff Finds No Major Concerns With Galleri Cancer Test

Grail's shares surged significantly on Monday after U.S. Food and Drug Administration staff reviewers released documents that did not raise major safety or accuracy concerns about the company's Galleri multi-cancer blood test. The briefing materials were published ahead of a key advisory panel meeting to discuss the test's potential approval.

Favorable FDA Staff Review Boosts Shares

Stock in Grail (GRAL) climbed by 35% following the release of the FDA briefing documents. According to the materials, agency staff have no outstanding questions for an external panel regarding Galleri's analytical performance, study design, or primary safety analyses.

The positive review comes as a welcome development for investors. Grail's stock had previously plunged more than 20% since February after a pivotal three-year UK trial failed to show the test significantly boosted early cancer detection or reduced late-stage diagnoses.

Upcoming Advisory Panel Review

The staff findings were prepared for a meeting of the FDA's external advisers scheduled for Wednesday. The panel will review Grail's application for premarket approval of the Galleri test, which is designed to detect signals from more than 50 types of cancer from a single blood draw.

Ad

While the review was largely positive, the agency did ask the advisory panel to discuss whether the available evidence supports characterizing Galleri as an "early detection" test. In a note to clients, Piper Sandler analyst David Westenberg called the documents "constructive for Grail" and said he expects a favorable vote from the panel.

The Path to Widespread Adoption

An official FDA approval is a critical milestone for multi-cancer early detection (MCED) tests. While Galleri is already available in the U.S. under Clinical Laboratory Improvement Amendments (CLIA) regulations, full FDA approval is considered essential for securing widespread physician adoption, inclusion in medical guidelines, and routine health insurance coverage.

Grail has stated that the test is meant to complement, not replace, established screenings like mammograms and colonoscopies. The Galleri test generated $136.8 million in revenue in the U.S. in 2025, according to the company.